New combo attack on stubborn breast cancer
NCT ID NCT07410234
Summary
This study is for people with a type of breast cancer (HER2-negative) that did not shrink enough after two rounds of standard chemotherapy. Researchers want to see if adding an immunotherapy drug (toripalimab) and a very precise, high-dose radiation treatment can help eliminate more cancer before surgery. The goal is to see if this combination is safe and more effective at clearing cancer from the breast and lymph nodes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.